|11. Switch to an IL-12/23i biologic over abatacept (PICO 68)|Low (98–100, 103, 104)|
|Conditional recommendation based on low-quality evidence; may consider abatacept in patients with recurrent or serious infections.| |
|12. Switch to an IL-12/23i biologic over tofacitinib (PICO 77)|Low (98–100, 105)|
|---|---|